LockBody® Platform
Oncology
DiscoveryActive
Key Facts
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, founded in 2020, consolidates specialized biotech assets under a unified, capital-efficient corporate structure with a patient-centric mission. Its primary achievement is advancing a pipeline of oral OX2R agonists, led by ORX750, which is in Phase 2 studies for narcolepsy and idiopathic hypersomnia, targeting a fundamental biological pathway for wakefulness. The company's strategy employs focused, data-driven development teams for each asset to rapidly progress programs, supported by a leadership team with deep industry and scientific expertise. A significant recent development is the announced acquisition by Eli Lilly, validating the platform's potential.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |